Losartan potassium membrane controlled-release pellet capsule

Abstract

The invention relates to a losartan potassium membrane controlled-release pellet capsule. The controlled-release film of the pellet adopts Eurdragit NE 30D as a film forming material, the core of the controlled-release pellet contains high-expansibility low-substituted hydroxypropylcellulose and a pharmaceutically-acceptable excipient commonly used for controlled-release pellets, and optimally, the excipient is microcrystalline cellulose, wherein the weight percentage of the low-substituted hydroxypropylcellulose in the core of the controlled-release pellet is 10-40%. The controlled-release film of the controlled-release pellet includes the Eurdragit NE 30D and an anti-adherent talcum powder, the optimal ratio of the Eurdragit NE 30D to the talcum powder is 30:6, and the optimal coating weight gain is 19-36%. The core will obviously expand after absorbing water because of the containment of the low-substituted hydroxypropylcellulose highly expanding after contacting with water, so the controlled-release film is stretched, the thickness of the film is thinned, the apertures of water-pervious micro-pores are increased, the permeability is good, and the permeability decrease caused by film ageing is compensated, thereby the middle and later stage release speed is basically constant, the last stage residue is small, and a stable release performance is always maintained prior to the expiration date.

Description

technical field [0001] The invention relates to a losartan potassium membrane-controlled sustained-release pellet capsule, in particular to a losartan potassium membrane-controlled sustained-release pellet capsule containing low-substituted hydroxypropyl cellulose in the pellet core, belonging to the field of pharmaceutical preparations . Background technique [0002] Losartan potassium is an angiotensin II receptor (AT1 type) antagonist, which can block various pharmacological effects of endogenous and exogenous angiotensin II by selectively acting on AT1 receptors (Including promoting vasoconstriction, aldosterone release, etc.), for the treatment of high blood pressure. The basic clinical requirement for this type of drug is that it can control symptoms for a long time. [0003] Losartan Potassium is dissolved in water, and Merck & Co. has launched Losartan Potassium Common Tablets (trade name: Cozaar) administered once a day. Losartan potassium is a prodrug with a sho...

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problem of release decline caused by film aging of losartan potassium film-controlled sustained-release pellets prepared by aqueous dispersion coating, the present invention provides a film-controlled film that can maintain stable release performance throughout the validity period. Losartan Potassium Sustained-release Pellet Capsule Capsules are characterized in that the core of the pellet contains low-substituted hydroxypropyl cellulose with high water-swellability, and the sustained-release coating film is deformed by water-absorbing swelling, thereby offsetting the film aging

Images